Clinical Trials Logo

Candidiasis, Esophageal clinical trials

View clinical trials related to Candidiasis, Esophageal.

Filter by:
  • None
  • Page 1

NCT ID: NCT03993093 Completed - HIV Infections Clinical Trials

Prevalence of HIV +ve Cases With AIDS Defining Opportunistic Infections Among ART Naive Patients Attending ART Centre

ADC
Start date: June 1, 2019
Phase:
Study type: Observational

HIV patients are likely to suffer from opportunistic infections, in absence of highly active retroviral therapy. This happens due to lack of awareness of HIV status among patients or unresponsive to anti retroviral drugs. This study is for the prevalence of AIDS defining OIs among treatment naive HIV patients.

NCT ID: NCT01165320 Completed - Aspergillosis Clinical Trials

A Study of Caspofungin (MK-0991) in Japanese Children and Adolescents With Documented Candida or Aspergillus Infections (MK-0991-074)

Start date: July 6, 2010
Phase: Phase 2
Study type: Interventional

The study estimates the safety, efficacy, and pharmacokinetics of caspofungin (MK-0991) in Japanese children and adolescents with documented Candida or Aspergillus infections.

NCT ID: NCT00005921 Completed - HIV Infections Clinical Trials

A Study of the Side Effects of L-743,872 in Men With Candidal Esophagitis

Start date: n/a
Phase: N/A
Study type: Interventional

The purpose of this study is to see if it is safe to give L-743,872 to men with candidal esophagitis, an AIDS-related yeast infection in the esophagus.

NCT ID: NCT00002339 Completed - HIV Infections Clinical Trials

A Study of Fluconazole in the Treatment of Fungal Infections of the Throat in Patients With Weakened Immune Systems

Start date: n/a
Phase: Phase 3
Study type: Interventional

To determine the safety, toleration, and efficacy of fluconazole oral suspension in the treatment of esophageal candidiasis in immunocompromised patients, including those with AIDS.

NCT ID: NCT00002304 Completed - HIV Infections Clinical Trials

A Comparison of Fluconazole and Ketoconazole in the Treatment of Fungal Infections of the Throat in Patients With Weakened Immune Systems

Start date: n/a
Phase: N/A
Study type: Interventional

To compare the safety, tolerance, and effectiveness of fluconazole and ketoconazole in the treatment of candidal esophagitis in immunocompromised patients.

NCT ID: NCT00002132 Completed - HIV Infections Clinical Trials

Randomized, Controlled, Double-Blind Study of Itraconazole Oral Solution Versus Fluconazole Tablets for the Treatment of Esophageal Candidiasis.

Start date: n/a
Phase: N/A
Study type: Interventional

To evaluate the safety and efficacy of itraconazole oral solution versus fluconazole tablets for the treatment of esophageal candidiasis in immunocompromised patients.

NCT ID: NCT00002041 Completed - HIV Infections Clinical Trials

Evaluation of Amphotericin B in the Treatment of Biopsy Proven Candida Esophagitis in Immunocompromised Patients

Start date: n/a
Phase: N/A
Study type: Interventional

To determine the appropriate duration of amphotericin B therapy for Candida esophagitis. To compare the effectiveness of two different amphotericin B doses in the treatment of biopsy-proven Candida esophagitis. To determine if low-dose amphotericin B is less toxic than standard dose therapy during a limited treatment period. To evaluate pharmacokinetic and pharmacodynamic parameters of the two different dosing regimens.

NCT ID: NCT00000744 Completed - HIV Infections Clinical Trials

A Randomized, Prospective, Double-Blind Study Comparing Fluconazole With Placebo for Primary and Secondary Prophylaxis of Mucosal Candidiasis in HIV-Infected Women

Start date: n/a
Phase: N/A
Study type: Interventional

To compare the efficacy of fluconazole versus placebo for the prevention of Candida esophagitis and vaginal/oropharyngeal candidiasis, including a comparison of the development of clinical resistance. Fluconazole has been shown to be effective in preventing or suppressing candidiasis in HIV-negative women. An increasing likelihood of oral and esophageal candidiasis in conjunction with progressive immunosuppression raises the question of the potential role of prophylactic antifungal therapy in high-risk persons.